To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes.
Additional recommended knowledge
The exact mechanism of the immunomodulatory drugs (i.e. thalidomide, CC-4047/Actimid and lenalidomide) is not known. Apart from interfering with the immune system, they are also thought to act on angiogenesis.
Lenalidomide and bortezomib are considered therapeutic breakthroughs in myeloma, which generally carries a poor prognosis.
With myelodysplastic syndromes, the best results of lenalidomide were obtained in patients with deletion 5q (List et al 2005).
It was approved by the FDA on December 27, 2005 for patients with low or intermediate-1 risk MDS with 5q- with or without additional cytogenetic abnormalities. On June 29, 2006, Revlimid (lenalidomide) received FDA clearance for use in combination with dexamethasone in patients with multiple myeloma who have received at least one prior therapy.
Mechanism of action
The exact mechanism by which Lenalidomide acts as an immunomodulatory agent is unknown. However, recent evidence suggests that it enhances ligand-dependent expansion of a subset of T cell, the Natural killer T cell, that responds to lipid antigens and is thought to be involved in immune tolerance, tumor immunosurveilance, modulation of autoimmunity, and protection from infection.
It is currently being tested in at least one study for treating some types of amyloidosis.
Lenalidomide is related to Thalidomide, and considered to be teratogenic. It has the pregnancy category X and cannot be prescribed for women who are pregnant or who might be conceiving. For this reason, the drug is only available through a restricted distribution system called RevAssistSM.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lenalidomide". A list of authors is available in Wikipedia.|